Einstein-Mount Sinai Diabetes Research Center

Pilot & Feasibility Study Program

Contact Information

Streamson Chua, MD, PhD
streamson.chua@einstein.yu.edu 

 

Pilot and feasibility awards of up to $50,000 annually for up to two years are available for new projects that explore a diabetes-related concept. Basic and translational projects related to diabetes are eligible. These funds are intended to enable investigators from Einstein, Mt. Sinai, and other affiliated NYC Institutions to generate preliminary data by providing extramural funding for their project. Pilot and feasibility funds are not intended to support or supplement ongoing diabetes research programs.

The start date for funding of successful applications is anticipated to be April 1, 2016.

Eligibility

Recipients are required to hold the rank of Assistant Professor or higher at the time of the award.

The program is designed to support:

  1. New investigators with interests in diabetes or related metabolic and endocrine disorders, including junior investigators shifting from mentor-based research to an independent career. Meritorious applications from new investigators receive priority for funding.
  2. Established faculty in other areas who wish to apply their expertise to diabetes research.
  3. Diabetes Center members who wish to explore a new area of research that constitutes a substantive departure from their on-going work.

Criteria

A proposed pilot and feasibility study should:

  1. Present a testable hypothesis and clearly delineate the question being asked
  2. Detail the procedure to be followed
  3. Discuss how the data will be analyzed

Funding

The budget for the first year (of a possible two-year funding period) can be up to $50,000. Requests for institutional indirect costs are prohibited and salary support for the investigator is generally not provided, except under circumstances that must be pre-approved before submission. Renewal for a second year of funding is contingent on adequate progress. Recipients are required to submit a brief progress report and present their research progress at one of the weekly Diabetes Research Center “Work in Progress” Seminars.

Application

Applications must include:

  1. abstract
  2. budget
  3. research plan (under 5 pages)
  4. other support data
  5. NIH biosketches for all key personnel

Applicants should provide these components as a single Word or PDF document. Applicants submitting in PDF should include a copy of the abstract in Word. Applicants must use the NIH Public Health Service 398 grant application forms from the NIH website. download forms 

No internal grant forms or approval signatures are necessary in order to submit an application. However, if CCI approval is needed for protection of human subjects, then applicants should apply for that approval at the time the proposal is submitted.

Applications should be submitted as e-mail attachments to Fran Taibi, fran.taibi@einstein.yu.edu by February 12, 2016.

Recent Pilot and Feasibility Program Studies

2015-2016 

  • Streamson Chua, MD, PhD, Einstein
    FGF signaling and metabolic control
  • Liora S. Katz, PhD, Mt Sinai
    T3 and glucose signaling in β-cells and their effect on ChREBP mediated proliferation

2014-2015 

  • Daorong Feng, PhD, MS BS
    A critical Role for SNAP23 in adipocyte cell viability
  • Victor Schuster, MD
    Treating obesity by blocking metabolism of endogenous prostaglandins.
  • Kimberly Reidy, MD
    LKB1 effect on podocyte metabolism and structure in diabetic nephropathy.
  • Djamel Lebeche, PhD
    Targeting Diabetes with small molecule activators of SERCA.
2013-2014
  • Role of Monocytes in Memory CD8+T and NK Cell-mediated Type 1 Diabetes
    Gregoire Lauvau, Ph.D.
  • miR-142-Regulated Vaccine for Boosting Islet Tolerance
    Brian Brown, Ph.D.
  • Treating obesity by blocking metabolism of endogenous prostaglandins
    Victor L. Schuster, MD
  • LKB1 effect on podocyte metabolism and structure in diabetic nephropathy
    Kimberly J Reidy, MD
  • Targeting Diabetes with small molecule activators of SERCA
    Djamel Lebeche, PhD
  • A Critical Role for SNAP23 in Adipocyte Cell Viability
    Daorong Feng, PhD, MS BS
2012-2013
  • High Fat Diet-induced Adipose Tissue Fibrosis
    Hyok Joon Kwon, PhD
  • Role of Endogenous SIRT1 Regulations in Glucose Homeostasis and Insulin Action
    Colette Knight, M.D.
  • South Asians Acting Together for Health Improvement (SAATHI)
    Alison Karasz, Ph.D.
  • BCL6 as a Novel Regulator of Glucose Metabolism
    Hilda Ye, Ph.D.

2011-2012 

  • Immune & Metabolic Mechanism in Spontaneous Obesity
    Xingxing Zang, M.Med, Ph.D.
  • Allograft Inflammatory Factor-1 and Obesity
    Nicholas Sibinga, Ph.D.

2010-2011 

  • Herbert Tanowitz, MD
    Chagas Diseases and Diabetes
  • Bhaskar Das, PhD
    A Novel Role of SIRT1 in Regulating Lipid Homeostasis
  • Fajun Yang, PhD
    Mechanisms of CDK8 Regulation on Lipogenesis
  • Claire Bastie, PhD
    Fyn Kinase-Dependent Regulation of LKB1
  • Laura Bocai, MD
    Effect of Insulin on Cardiovascular Complications of Type 2 Diabetes in ACCORD  

2008-2009 

  • Jeffrey Gonzalez, PhD        
    Reducing Distress and Improving Treatment Adherence in Type 1 Diabetes.
  • Liang Zhu, MD, PhD
    Role of Rb In Obesity and Diabetes Through Regulation of Hypothalamic Neurons.

2007-2008 

  • Richard Kitsis, MD
    ARC and Beta-Cell Apoptosis: Molecular Mechanisms and Physiological Significance
  • Steve Almo, PhD
    Multivalent Peptide-MHC Constructs for Treating Diabetes
  • Tao Wang, PhD
    Genetic Link Between Type 2 diabetes and Postmenopausal Breast Cancer
  • David Silver, PhD
    Role of FIT Proteins in Obesity and Insulin Resistance
Click here to log in